{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}]}],"title":"Any TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"}]}],"title":"Treatment-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}],"title":"Any Treatment-Emergent SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Discontinuation of treatment due to TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"}]}],"title":"Discontinuation of treatment due to treatment-related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"TEAE leading to death"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a patient or clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Treatment emergent AEs (TEAEs) are defined as events that are new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment.","groups":[{"description":"Participants with classic Hodgkin lymphoma","id":"OG000","title":"Classic Hodgkin Lymphoma"},{"description":"Participants with peripheral T cell lymphoma","id":"OG001","title":"PTCL"}],"paramType":"NUMBER","populationDescription":"The full analysis set includes participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 36 months","title":"Number of Participants With Adverse Events","type":"PRIMARY","unitOfMeasure":"Participants"}